Table 4. Anti-HIV-1 activity of nucleoside analogues in Vpx expressing THP1 cells.

Nucleoside analogue	PMA−				PMA+
	EC50 (μM)a [95% CI]b		Fold	pc	EC50 (μM) [95% CI]		Fold	p
	Vpx−	Vpx+			Vpx−	Vpx+
ACV	>200	>200	—	—	1.08 [0.735–1.43]	29.6 [2.62–56.5]	27	0.0004
GCV	>200	>200	—	—	0.632 [0.596–0.668]	>200	>316	<0.0001
CFB	0.340 [0.118–0.563]	>1.6	>5	<0.0001	0.003 [0.002–0.004]	0.012 [0.003–0.021]	4	0.0017
d4T	4.39 [3.76–5.02]	13.3 [12.1–14.4]	3	0.0001	1.49 [0.501–2.48]	52.2 [33.0–71.5]	35	0.0009
ddI	1.04 [0.863–1.22]	2.73 [1.40–4.07]	3	0.0039	0.079 [0.061–0.096]	4.34 [3.19–5.50]	55	0.0005
ABC	0.459 [0.399–0.519]	0.622 [0.356–0.888]	1	0.0619†	0.038 [0.036–0.040]	7.050 [4.67–9.43]	187	0.0002
NVP	0.244 [0.240–0.248]	0.292 [0.067–0.517]	1	0.1146†	0.223 [0.196–0.250]	0.235 [0.217–0.253]	1	0.0379†
RAL	0.035 [0.017–0.053]	0.043 [0.016–0.070]	1	0.0683†	0.038 [0.020–0.056]	0.037 [0.002–0.072]	1	0.9071†

^aEC₅₀ is the effective concentration of drug that inhibits infection of cells by 50% measured as the percentage of GFP⁺ cells in Vpx⁻ or Vpx⁺ populations. Values were calculated by non-linear regression for at least two independent experiments.

^b95% confidence interval. Non-ambiguous values were subject to a replicate test.

^cEC₅₀ values for each replicate were used to perform an unpaired two-tailed t-test to determine differences between Vpx⁻ and Vpx⁺ populations.

^†Difference not statistically significant.